Aug 26, 2011
Acquisition Complements Baxter’s Broad Nutrition and Drug Delivery Portfolio
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) announced today that it has entered into a definitive agreement to acquire Baxa Corporation, a privately held company based in Englewood, Colo., with additional operations in Florida and the United Kingdom. Baxa develops pharmacy technology that enhances the efficiency and safety of oral and IV dose preparation and delivery. The addition of Baxa’s product lines will complement Baxter’s portfolio of nutrition products and drug delivery systems and supports patient safety.
“With these new offerings, Baxter will be able to provide a comprehensive solution to fulfill the majority of patients’ nutritional requirements and increase efficiency in the pharmacy,” said Robert M. Davis, president of Baxter’s Medical Products business. “Bringing this expertise together with Baxter’s commercial capabilities and global reach will enable us to continue to meet our customers' evolving needs and extend our position in IV nutrition and fluid delivery.”
The transaction includes a total upfront cash consideration of $380 million and is expected to close following satisfaction of customary closing conditions and the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Annual sales for Baxa were approximately $150 million in 2010, and Baxter expects the future top-line growth of this business to be accretive to the company’s future sales growth. In addition, Baxter expects this transaction to be neutral to full-year 2012 earnings excluding dilution of approximately $0.03 to $0.05 per diluted share related to acquisition accounting and transaction-related expenses, and increasingly accretive thereafter.
Nutrition is recognized as an important element of patients’ therapy, and both Baxter and Baxa have sought to advance the delivery of IV nutrition through innovative technologies such as Baxter’s multi-chamber, premixed containers and Baxa’s automated compounding systems.
Baxter’s multi-chamber containers are prefilled and provide many of the essential ingredients of balanced nutrition for a wide range of patients. Baxa’s pharmacy integration and automation technology allow hospital pharmacists to customize treatment for specific patient populations when needed.
In response to the growing need to eliminate sources of potential error, both premixed medications and pharmacy automation help to reduce medication errors and improve operational effectiveness. Among Baxa’s numerous offerings are the ExactaMix® Compounder, devices that automate multi-ingredient nutritional solution compounding and the DoseEdge® Pharmacy Workflow Manager, an integrated system for managing IV and oral dose preparation activities.
Baxa products play a trusted role in the preparation of hundreds of thousands of safe doses of medication every day. “With this agreement, Baxa will be able to play a greater role in delivering safe medication practices,” said Greg Baldwin, Baxa chairman and chief executive officer. “We are very pleased to find a partner that shares our commitment and sees the potential in our products, technology and people.”
About Baxter’s Medical Products Business
Baxter’s Medical Products business develops and provides products used in the delivery of fluids and drugs to patients. These include IV solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps, inhalation anesthetics and products and services for people with end-stage kidney disease. At the forefront of IV nutrition, Baxter’s ongoing advancements include multi-chamber containers, lipids, amino acids, vitamins and admixing technology.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
This release includes forward-looking statements concerning a definitive agreement entered into between the company and Baxa, including expectations with respect to the closing of the transaction and its financial impact on the company. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; product quality or patient safety issues; failure to obtain the necessary consents or to satisfy other closing conditions; and other risks identified in the company's most recent filing on Form 10-K and other SEC filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements.
Baxter International Inc.
Christy Noland, (847) 948-4380
Deborah Spak, (847) 948-2349
Mary Kay Ladone, (847) 948-3371
Clare Trachtman, (847) 948-3085
|Jan 18, 2018||Winland Hires Manager of the Reseller Partner Channel|
|Jan 10, 2018||American Associated Pharmacies Selects FDS ECONCILE Reconciliation and Claims Ma...|
|Dec 27, 2017||RxOneShop Is Proud to Sponsor and Invite You to Pharmacy Owners Boot Camp|
|Dec 20, 2017||UPMC Chooses Revolutionary Technology from Omnicell to Elevate and Automate Phar...|
|Dec 18, 2017||Medicine-On-Time Announces Long-Term Distribution Partnership and Purchase of Ma...|
|Dec 14, 2017||iMedicare and Creative Pharmacist Announce Strategic Partnership|
|Dec 13, 2017||American BioTech Supply Introduces Webpages Dedicated to Natural Refrigerant Tec...|
|Dec 08, 2017||Azzur Labs Expands Accreditation|
|Dec 08, 2017||Azzur Labs Named Fourth Best Place To Work in PA|
|Dec 06, 2017||Hacettepe University Oncology Hospital Introduces Omnicell i.v.STATION ONCO Robo...|
|Dec 01, 2017||Swisslog Healthcare Launches Next-Generation Pharmacy Analytics Platform To Tran...|
|Nov 28, 2017||Omnicell Introduces Revolutionary New Solution to Automate Critical Workflows in...|
|Nov 22, 2017||R.J. Hedges & Associates Named 2017 Torch Award for Ethics by BBB|
|Nov 17, 2017||BestRx First Pharmacy Dispensing Software Company to Achieve Level 2 – Pharmac...|
|Nov 16, 2017||Introducing Accreditation Commission for Health Care as a Thought Leader in Phar...|
|Nov 15, 2017||Medi-Dose®, Inc. / EPS®, Inc. Now Markets Steri-Tamp® Tamper-Clear Syringe...|
|Nov 14, 2017||Omnicell Supports Global Charity Mercy Ships by Donating Next Generation XT Seri...|
|Nov 14, 2017||Medi-Dose, Inc. Announces NEW MPB™ Multi-Purpose Blister|
|Nov 13, 2017||OmniSYS Announces Strategic Partnership with PerceptiMed|
|Nov 02, 2017||Contec, Inc. Recognized as One of America's Healthiest Organizations by American...|
|Nov 02, 2017||Introducing Apexus as a Thought Leader in 340B Drug Pricing and Education|
|Oct 31, 2017||Medicine-On-Time and Clinical Support Services Announce the Formation of Star MT...|
|Oct 26, 2017||Hackensack Meridian Health Expands Contract with Omnicell for Medication Managem...|
|Oct 26, 2017||iMedicare and American Associated Pharmacies Partner to Help Independent Pharmac...|
|Oct 25, 2017||Medi-Dose, Inc. / EPS, Inc. Announces Expanded Line of Resealable and Ultraviole...|
|Oct 25, 2017||Riverside Medical Center Selects Omnicell's Medication Management Solutions to E...|
|Oct 25, 2017||Kinney Drugs 1st Patient-Centered Pharmacy Home™ Accreditation Recipient|
|Oct 24, 2017||Dana Rafferty Named Akro-Mils Executive Director of Sales and Marketing|
|Oct 23, 2017||Medi-Dose/EPS Announces TampAlerT® Tamper-Evident Cap for ENFit™ Syringes|
|Oct 20, 2017||Phononic Honored by Goldman Sachs for Entrepreneurship|
Connect with thousands of pharmacy professionals throughout every practice setting.